Drug Dev and Preclinical Studies
Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.
One shared journey is moving us forward at Bristol-Myers Squibb. Around the world, we are passionate about making an impact on the lives of patients with serious disease. Empowered to apply our individual talents and ideas so that we can learn and grow together. Driven to make a difference, from innovative research to hands-on community support. Bristol-Myers Squibb recognizes the importance of balance and flexibility in our work environment. We offer a wide variety of competitive benefits, services and programs that provide our employees the resources to pursue their goals, both at work and in their personal lives.
BMS Clinical Histochemistry Group is a diverse group of scientists in US/India who develop fit for purpose immunohistochemistry (IHC) assays to support early development and late stage clinical programs, and rationalize therapy decisions for BMS clinical trials in ImmunoSciences and Immuno-Oncology. We are deeply engaged in new technology identification and evaluations related to tissue-based assays, including multiplexed IHC or ISH (in situ hybridization), digital image analysis, deep learning and other emerging technologies critical to BMS continued scientific excellence in translational research.
BMS Clinical Histochemistry is seeking a motivated, interactive, and creative individual to join our Group as Senior Research Investigator. The successful candidate will have track record of IHC assay development and validation in a GCLP or related regulated environment. S/He will work closely with discovery and clinical biomarker scientists, early asset development leaders in BMS Translational Medicine, and pathologists to scope, develop and validate assays for clinical trials. They will be primarily accountable for the transition and/or modification of BMS IHC/ISH assays with outsource partners (CROs, CLIA).
The successful candidate will also be working with image analysts to assess assay suitability and endpoints for digital image analysis, and how to apply statistical methods to associate assay target expression with disease and clinical response.
Extensive knowledge of IHC principles, instruments and interpreting IHC stains in tissues is required.
Experience in monoplex and multiplex IHC/ISH (brightfield and fluorescence-based) assay development, from antibody selection and staining optimization to downstream digital and imaging strategies, is important.
Exposure to cancer immunotherapy including immune-checkpoint blockade with knowledge of current therapeutic landscape is highly desirable
Preference will be given to individuals with previous experience working in the fields of immunoscience, oncology and/or immuno-oncology and working in a GLP or GCLP environment.
Highly motivated and collaborative, with the ability to multitask and drive team achievement while working across multiple disciplines in a complex matrix organization.
Qualified candidates must have a M.S. or PhD. plus at least 5 years work experience in an academic or bio/pharma environment.
Excellent written and verbal communication skills and the ability to clearly communicate scientific objectives and project results are required.